Research location
Plasencia
Spain
Advertisement
Research activity in Plasencia
SpainCureCurrent currently publishes aggregate city-level research activity for this location: 10 trials and 11 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Plasencia
10 linked trials · page 1 of 1Assessment of the Effectiveness of IV and SC Abatacept (Orencia) Patient Alert Cards in Patients With Rheumatoid Arthritis in a Sample of EU CountriesNCT02632890 · 2016-11-29 · 2 site observations
COMPLETED
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's DiseaseNCT02760602 · 2016-06-01 · 1 site observation
TERMINATED
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus PlaceboNCT01900665 · 2013-07-01 · 1 site observation
TERMINATED
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's DiseaseNCT01127633 · 2010-12-01 · 1 site observation
TERMINATED
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary DiseaseNCT01126437 · 2010-05-01 · 1 site observation
COMPLETED
A Study of Semagacestat for Alzheimer's PatientsNCT01035138 · 2009-12-01 · 1 site observation
COMPLETED
A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)NCT00900731 · 2009-06-01 · 1 site observation
COMPLETED
Effect of LY2062430 on the Progression of Alzheimer's DiseaseNCT00904683 · 2009-05-01 · 1 site observation
COMPLETED
Effect of LY450139 on the Long Term Progression of Alzheimer's DiseaseNCT00594568 · 2008-03-01 · 1 site observation
COMPLETED
Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/GlibenclamideNCT00279045 · 2000-01-03 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.